Statistics from Altmetric.com
- Hepatitis B virus
- quantitative anti-HBc
- treatment response prediction
- hepatitis B
- hepatitis E
- infectious disease
- hepatitis C
- hepatocellular carcinoma
- hepatitis D
- liver disease in pregnancy
We read with interest the recent article by Dandri emphasising the use of novel quantitative biomarkers as tools for predicting treatment response and disease progression in chronic hepatitis B infection (CHB).1 The authors carried out a comprehensive review of the clinical implications of quantitative measurement of viral biomarkers both in blood and in liver, such as: serum HBsAg, serum HBeAg and intrahepatic cccDNA, based on current knowledge.1 In addition to these, …
Funding Supported by grants from the National Scientific and Technological Major Project (2012ZX10002-005); and acknowledgement of Taiwan Liver Consortium for patients recruitment.
Competing interests P-J Chen is a consultant for Novartis and Roche. D-S Chen is a consultant for Novartis and GlaxoSmithKline. J-H Kao is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Omrix, and Roche; and is a member of the Speaker's Bureau for Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Novartis.
Patient consent Obtained.
Ethics approval This study was approved by the Ethics Committees of Zhongshan Hospital of Xiamen University.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.